UNSPSC 51401509: Meclonazepam

This classification denotes a benzodiazepine with the molecular formula C16H12ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RN43209SMA, chemically known as 5-(2-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2h-1,4-benzodiazepin-2-one but generally known as meclonazepam, which bears US NIH Compound Identifier 93364. European Medicines Agency schedules Meclonazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08680MIG.

UNSPSC 51401509 Meclonazepam, a Commodity code, shows limited alignment with recent state and local procurement activity. The code nominally describes a specific controlled pharmaceutical, but the single recent opportunity tagged under it — Seminole County, Florida's IFB60459723LAS — actually solicits naloxone and safe drug deactivation systems for community health initiatives, not meclonazepam. The mismatch suggests either a data-entry error in the opportunity's code assignment or that meclonazepam procurement through state and local channels is not currently active in the available record. Procurement under this code does not appear to be a meaningful target right now based on available recent solicitations.

Seminole County posted the naloxone and drug-deactivation-system IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems on an annual basis through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The county required vendors to submit bids electronically, include all shipping and delivery costs in their proposals, hold appropriate insurance coverages, maintain E-Verify compliance, and accept a three-month probationary period with potential termination without cause. The initial contract term was two years with an optional one-year renewal. No explicit set-aside or disadvantaged-enterprise designations were noted in the procurement.